CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.59 USD
-0.01 (-0.63%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CTMX 1.59 -0.01(-0.63%)
Will CTMX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CTMX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTMX
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
GSK Gears Up for Q1 Earnings: Here's What to Expect
CTMX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Viking (VKTX) to Report Q1 Earnings: What's in the Cards?
Other News for CTMX
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
CytomX upgraded to Neutral at J.P. Morgan
CytomX upgraded to Neutral at J.P Morgan
CytomX Therapeutics just upgraded at JPMorgan, here's why
Analysts Offer Insights on Healthcare Companies: Cyclo Therapeutics (CYTH), CytomX Therapeutics (CTMX) and Pacific Biosciences (PACB)